INSM - NASDAQ
Insmed Incorporated
$103.86
+0.13%Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
At a Glance
Live SnapshotInsmed Incorporated Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Insmed Incorporated Income Statement
INSM • NASDAQ
| Insmed Incorporated Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
606.4M | 363.7M | 305.2M | 245.4M | 188.5M | 164.4M | 136.5M | 9.8M | 0.0 | 0.0 | 0.0 | 11.5M | 11.5M | 0.0 | 4.4M | 6.9M | 10.4M | 11.7M | 7.5M | 991K | |
GROSS PROFIT | ||||||||||||||||||||
(124.9M) | (85.7M) | (65.6M) | (55.1M) | (44.2M) | (39.9M) | (24.2M) | (2.4M) | (2.9M) | (2.4M) | (2M) | (33.5M) | (0.0) | (21.4M) | (0.0) | (0.0) | (0.0) | (0.0) | (576K) | (1.5M) | |
481.5M | 278M | 239.6M | 190.2M | 144.3M | 124.5M | 112.3M | 7.4M | -2.9M | -2.4M | -2M | -22M | 0.0 | -21.4M | 4.4M | 6.9M | 10.4M | 11.7M | 7M | -499K | |
OPERATING INCOME | ||||||||||||||||||||
(1.7B) | (1.2B) | (949.3M) | (647.6M) | (519.4M) | (389.8M) | (347.5M) | (314.8M) | (188.9M) | (173.4M) | (117.5M) | (87.4M) | (66.5M) | (42.4M) | (66.1M) | (15M) | (19M) | (26.1M) | (27.4M) | (53.9M) | |
(701.2M) | (461.1M) | (344.5M) | (265.8M) | (234.3M) | (203.6M) | (210.8M) | (168.2M) | (79.2M) | (50.7M) | (43.2M) | (31.1M) | (18.6M) | (12.7M) | (11.5M) | (10.3M) | (9.8M) | (5.1M) | (8.5M) | (25.7M) | |
(771.1M) | (598.4M) | (571M) | (397.5M) | (272.7M) | (181.2M) | (131.7M) | (145.3M) | (109.7M) | (122.7M) | (74.3M) | (56.3M) | (44.3M) | (29.8M) | (28.6M) | (4.7M) | (9.2M) | (21M) | (18.9M) | (21.1M) | |
-1.2B | -878.3M | -709.6M | -457.3M | -375.1M | -265.2M | -235.2M | -307.3M | -188.9M | -173.4M | -117.5M | -87.4M | -55M | -42.4M | -61.7M | -8.1M | -8.7M | -14.4M | -20.4M | -54.4M | |
PRE-TAX INCOME | ||||||||||||||||||||
(83.8M) | (84.9M) | (81.7M) | (26.4M) | (40.5M) | (29.6M) | (27.7M) | (25.5M) | (5.9M) | (3.5M) | (2.9M) | (2.4M) | (2.4M) | (763K) | (10K) | (109K) | (781K) | (1.3M) | (682K) | (3.7M) | |
-23.1M | -31.6M | -39.6M | -15.4M | -40.3M | -27.9M | -17.8M | -15.1M | -4.3M | -2.9M | -2.6M | -2.4M | -2.2M | 1.1M | -10K | -109K | -781K | -756K | 477K | -1.8M | |
(186M) | (96.7M) | (33.7M) | -15.7M | (12.4M) | (5M) | (5M) | (1.2M) | (300K) | (119K) | -33K | (141K) | (3.6M) | (0.0) | (26M) | (0.0) | (0.0) | (0.0) | (0.0) | (7.1M) | |
-95M | -31.8M | -37.4M | -22.8M | -61.3M | -27.5M | -18.3M | -16.7M | -4M | -2.8M | -2.7M | -2.2M | -2.3M | -1.1M | 2.1M | 1.7M | 127.5M | -1.3M | 20.4M | 54.4M | |
-1.3B | -910.1M | -747M | -480.2M | -436.4M | -292.7M | -253.6M | -324.1M | -192.9M | -176.2M | -120.2M | -89.6M | -57.3M | -41.4M | -59.7M | -6.4M | 118.8M | -15.7M | 0.0 | 0.0 | |
NET INCOME | ||||||||||||||||||||
(5M) | (3.7M) | (2.6M) | (1.4M) | -1.8M | (1.4M) | (777K) | (201K) | -272K | (98K) | -2M | -10.4M | -1.2M | (763K) | (0.0) | (78K) | (477K) | (0.0) | (0.0) | (0.0) | |
-1.3B | -913.8M | -749.6M | -481.5M | -434.7M | -294.1M | -254.3M | -324.3M | -192.6M | -176.3M | -118.2M | -79.2M | -56.1M | -41.4M | -59.7M | -6.4M | 118.4M | -15.7M | -20M | -56.1M |
SEC Filings
INSM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 17, 2025 | December 17, 2025 | 2025 |
Related Guides
Continue your INSM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.